Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$27,000.00
Effectiveness and safety of glucagon-like peptide-1 receptor agonists in patients with inflammatory arthritis and type 2 diabetes mellitus
FY 2024-25
Summary
Nearly one-third of Canadian adults have obesity. Carrying excess weight results in inflammation that can increase a person risk of heart disease, diabetes, and death. For people with existing inflammatory diseases, like those living with inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis), the pro-inflammatory effect of excess fat can also make their disease more active and resistant to treatment. Diabetes medications called glucagon-like peptide-1 receptor agonists (GLP-1-RAs, like semaglutide) are effective in reducing excess weight and inflammation, but studies looking at how these drugs affect people living with inflammatory arthritis are lacking. By lowering weight and inflammation, could they reduce needs for immune suppressing medications that patients with inflammatory arthritis often need to take? Are they safe in these patients? To answer these questions, we will use administrative health data from British Columbia and compare patients with diabetes and inflammatory arthritis who are newly starting either a GLP-1-RA or a different type of diabetes drug that does not affect weight. We will compare the number of people in each group who need to increase their immune suppressing medications, as well as the number who are able to decrease them. Because there have been safety concerns around GLP-1-RA use and depression, suicidal thoughts, and diseases of the pancreas and gallbladder, we will also assess how often people taking GLP-1-RAs (vs. those taking the other type of diabetes drug) visited emergency rooms, were hospitalized, or died from these causes. This study will provide important safety data on an increasingly popular drug class and may support the pursuit of more studies to confirm a benefit if one is found.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530301
Name
Karacabeyli Derin
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effectiveness and safety of glucagon-like peptide-1 receptor agonists in patients with inflammatory arthritis and type 2 diabetes mellitus
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Administrative Health Data; Axial Spondyloarthritis; Dipeptidyl Peptidase-4 (Dpp4) Inhibitor; Glucagon-Like Peptide-1 (Glp-1) Receptor Agonist; Obesity; Pharmacoepidemiology; Population-Based Study; Psoriatic Arthritis; Rheumatoid Arthritis; Target Trial Emulation
Abstract
Nearly one-third of Canadian adults have obesity. Carrying excess weight results in inflammation that can increase a person risk of heart disease, diabetes, and death. For people with existing inflammatory diseases, like those living with inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis), the pro-inflammatory effect of excess fat can also make their disease more active and resistant to treatment. Diabetes medications called glucagon-like peptide-1 receptor agonists (GLP-1-RAs, like semaglutide) are effective in reducing excess weight and inflammation, but studies looking at how these drugs affect people living with inflammatory arthritis are lacking. By lowering weight and inflammation, could they reduce needs for immune suppressing medications that patients with inflammatory arthritis often need to take? Are they safe in these patients? To answer these questions, we will use administrative health data from British Columbia and compare patients with diabetes and inflammatory arthritis who are newly starting either a GLP-1-RA or a different type of diabetes drug that does not affect weight. We will compare the number of people in each group who need to increase their immune suppressing medications, as well as the number who are able to decrease them. Because there have been safety concerns around GLP-1-RA use and depression, suicidal thoughts, and diseases of the pancreas and gallbladder, we will also assess how often people taking GLP-1-RAs (vs. those taking the other type of diabetes drug) visited emergency rooms, were hospitalized, or died from these causes. This study will provide important safety data on an increasingly popular drug class and may support the pursuit of more studies to confirm a benefit if one is found.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Karacabeyli, Derin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~